JP4209472B2
(ja)
*
|
1997-06-02 |
2009-01-14 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
平滑筋細胞増殖のインヒビターとしての(イミダゾール−5−イル)メチル−2−キノリノン誘導体
|
US6565831B1
(en)
|
1999-02-24 |
2003-05-20 |
Oncolytics Biotech Inc. |
Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
|
US6136307A
(en)
|
1997-08-13 |
2000-10-24 |
Oncolytics Biotech Inc. |
Reovirus for the treatment of cellular proliferative disorders
|
US6110461A
(en)
|
1997-08-13 |
2000-08-29 |
Oncolytics Biotech Inc. |
Reovirus for the treatment of neoplasia
|
WO1999029674A1
(fr)
|
1997-12-11 |
1999-06-17 |
Janssen Pharmaceutica N.V. |
Anilides mimetiques de l'acide retinoique
|
US6420555B1
(en)
|
1998-06-16 |
2002-07-16 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Imidazolyl derivatives
|
DK1097150T3
(da)
*
|
1998-06-16 |
2004-07-26 |
Sod Conseils Rech Applic |
Imidazolylderivater
|
CA2336624C
(fr)
*
|
1998-07-06 |
2008-10-21 |
Janssen Pharmaceutica N.V. |
Inhibiteurs de farnesyl proteine transferase a proprietes de radiosensibilisation in vivo
|
BR9911869A
(pt)
|
1998-07-06 |
2001-03-27 |
Janssen Pharmaceutica Nv |
Inibidores da transferase da proteìna farnesil para o tratamento das artropatias
|
FR2780892B1
(fr)
*
|
1998-07-08 |
2001-08-17 |
Sod Conseils Rech Applic |
Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
|
ES2237125T3
(es)
|
1998-08-27 |
2005-07-16 |
Pfizer Products Inc. |
Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
|
JP3495706B2
(ja)
*
|
1998-08-27 |
2004-02-09 |
ファイザー・プロダクツ・インク |
抗癌薬として有用なアルキニル置換キノリン−2−オン誘導体
|
WO2000034239A2
(fr)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibiteurs de prenyl-proteine transferase
|
AU2477400A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
IL143859A0
(en)
*
|
1998-12-23 |
2002-04-21 |
Janssen Pharmaceutica Nv |
1,2-annelated quinoline derivatives
|
EP1150973B1
(fr)
|
1999-02-11 |
2005-06-15 |
Pfizer Products Inc. |
Derives de quinolin-2-one a substitution heteroaryle convenant comme anti-cancereux
|
US6143766A
(en)
*
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
EP1420015A1
(fr)
*
|
1999-06-11 |
2004-05-19 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Dérivés de l'imidazole
|
DE60008206T2
(de)
|
1999-11-30 |
2004-12-02 |
Pfizer Products Inc., Groton |
Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
|
HN2000000266A
(es)
*
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
WO2001062234A2
(fr)
|
2000-02-24 |
2001-08-30 |
Janssen Pharmaceutica N.V. |
Regime posologique
|
JP2003525238A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
|
EP1261348A2
(fr)
*
|
2000-02-29 |
2002-12-04 |
Janssen Pharmaceutica N.V. |
Combinaisons d'inhibiteur de farnesyl proteine transferase et d'agents d'alkylation antitumoraux
|
JP2003525245A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
|
JP2003525234A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
|
CA2397690A1
(fr)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Inhibiteur de farnesyl proteine transferase associe a des derives nucleosidiques anti-cancereux
|
AU2001254672A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with an her2 antibody
|
US20030027808A1
(en)
*
|
2000-02-29 |
2003-02-06 |
Palmer Peter Albert |
Farnesyl protein transferase inhibitor combinations with platinum compounds
|
WO2001064196A2
(fr)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Combinaisons d'inhibiteurs de farnesyl proteine transferase et de vinca-alcaloides
|
WO2001064197A2
(fr)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Combinaisons d'inhibiteurs de farnesyl proteine transferase et de derives antitumoraux d'anthracycline
|
AU2001244166A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
|
AU2001246478A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with taxane compounds
|
US6844357B2
(en)
*
|
2000-05-01 |
2005-01-18 |
Pfizer Inc. |
Substituted quinolin-2-one derivatives useful as antiproliferative agents
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
WO2002024682A1
(fr)
*
|
2000-09-25 |
2002-03-28 |
Janssen Pharmaceutica N.V. |
Derives de quinoline et de quinazoline inhibant la farnesyl transferase comme inhibiteurs de farnesyl transferase
|
AU2001293829A1
(en)
*
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
|
US7067531B2
(en)
*
|
2000-09-25 |
2006-06-27 |
Angibaud Patrick Rene |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
AU2002214056A1
(en)
*
|
2000-11-21 |
2002-06-03 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting benzoheterocyclic derivatives
|
PT1339407E
(pt)
*
|
2000-11-28 |
2006-08-31 |
Janssen Pharmaceutica Nv |
Inibidores da proteina farnesil transferase para o tratamento de doenca inflamatoria do intestino
|
BR0116302A
(pt)
|
2000-12-19 |
2004-01-13 |
Pfizer Prod Inc |
Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção
|
US7129356B2
(en)
|
2000-12-27 |
2006-10-31 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
|
DE60119383T2
(de)
*
|
2000-12-27 |
2007-04-19 |
Janssen Pharmaceutica N.V. |
Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
|
US20040110769A1
(en)
*
|
2001-02-15 |
2004-06-10 |
End David William |
Farnesyl protein transferase inhibitor combinations with antiestrogen agents
|
JP4257698B2
(ja)
|
2001-03-12 |
2009-04-22 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
イミダゾール化合物の製造方法
|
US6740757B2
(en)
|
2001-08-29 |
2004-05-25 |
Pfizer Inc |
Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
|
ES2323265T3
(es)
|
2001-12-19 |
2009-07-10 |
Janssen Pharmaceutica Nv |
Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
|
AU2003223970B2
(en)
|
2002-03-22 |
2008-03-06 |
Janssen Pharmaceutica N.V. |
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
|
CA2481480C
(fr)
|
2002-04-15 |
2011-04-12 |
Janssen Pharmaceutica N.V. |
Derives de quinazoline tricylique inhibant la farnesyl transferase substitues avec des imidazoles ou des triazoles a liaison carbone
|
FR2841243B1
(fr)
*
|
2002-06-19 |
2004-08-20 |
Servier Lab |
Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US20030125268A1
(en)
*
|
2002-08-28 |
2003-07-03 |
Rybak Mary Ellen Margaret |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
FR2860235A1
(fr)
*
|
2003-09-29 |
2005-04-01 |
Yang Ji Chemical Company Ltd |
Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
ATE531367T1
(de)
*
|
2004-09-17 |
2011-11-15 |
Whitehead Biomedical Inst |
Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
|
PT1815247E
(pt)
|
2004-11-05 |
2013-04-23 |
Janssen Pharmaceutica Nv |
Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US20060281769A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
|
US20060281755A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
|
US20070004660A1
(en)
*
|
2005-06-10 |
2007-01-04 |
Baumann Christian A |
Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
|
US7833339B2
(en)
|
2006-04-18 |
2010-11-16 |
Franklin Industrial Minerals |
Mineral filler composition
|
EP1968591A4
(fr)
|
2005-12-23 |
2010-02-17 |
Link Medicine Corp |
Traitement de formes de synucleinopathie
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
ES2565238T3
(es)
|
2006-04-20 |
2016-04-01 |
Janssen Pharmaceutica N.V. |
Inhibidores de la c-fms quinasa
|
PT2021335E
(pt)
|
2006-04-20 |
2011-07-25 |
Janssen Pharmaceutica Nv |
Compostos heterocíclicos como inibidores de c-fms quinase
|
DE102007015709B4
(de)
|
2007-01-25 |
2009-09-03 |
Webasto Ag |
Fahrzeugdach
|
MX2009013333A
(es)
|
2007-06-05 |
2010-01-18 |
Schering Corp |
Derivados de indazol policiclicos y su uso como inhibidores de erk para el tratamiento de cancer.
|
JO3240B1
(ar)
*
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
US8232402B2
(en)
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
WO2009117484A2
(fr)
|
2008-03-18 |
2009-09-24 |
University Of South Florida |
Petite molécule inhibitrice d'e2f
|
BRPI0920927A2
(pt)
|
2008-11-13 |
2019-09-24 |
Link Medicine Corp |
derivados de azaquinolinona e usos dos mesmos
|
AU2010300925A1
(en)
|
2009-09-30 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
EP2555766A4
(fr)
|
2010-04-06 |
2015-06-03 |
Univ Brigham Young |
Composés antimétastatiques
|
WO2011163330A1
(fr)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
|
AU2011282614B2
(en)
|
2010-07-28 |
2015-11-26 |
Janssen Pharmaceutica Nv |
Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
|
CA2808841A1
(fr)
*
|
2010-08-24 |
2012-03-01 |
Brigham Young University |
Composes antimetastatiques
|
WO2012030685A2
(fr)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
|
WO2012087772A1
(fr)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
|
CN103906751A
(zh)
*
|
2011-10-02 |
2014-07-02 |
波士顿大学董事会 |
作为晚期SV40因子(LSF)抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
US9303046B2
(en)
|
2012-08-07 |
2016-04-05 |
Janssen Pharmaceutica Nv |
Process for the preparation of heterocyclic ester derivatives
|
US10653672B2
(en)
|
2014-02-07 |
2020-05-19 |
National University Corporation Tokyo Medical And Dental University |
Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
|
PT3277842T
(pt)
|
2015-08-17 |
2019-09-05 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
EP3133065A1
(fr)
|
2015-08-21 |
2017-02-22 |
Merck Patent GmbH |
Composés de dispositifs optiquement actifs
|
EP3133066A1
(fr)
*
|
2015-08-21 |
2017-02-22 |
Merck Patent GmbH |
Composés hydrophiles pour dispositifs optiquement actifs
|
US9815790B2
(en)
|
2015-08-27 |
2017-11-14 |
Janssen Pharmaceutica Nv |
Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
|
EP3838275A1
(fr)
|
2016-11-03 |
2021-06-23 |
Kura Oncology, Inc. |
Inhibiteurs de farnésyltransférase pour utilisation dans le traitement de cancer
|
EP3363786A1
(fr)
|
2017-02-15 |
2018-08-22 |
Merck Patent GmbH |
Composés de dispositifs optiquement actifs
|
EP3363793A1
(fr)
|
2017-02-15 |
2018-08-22 |
Merck Patent GmbH |
Composés hydrophobes pour dispositifs optiquement actifs
|
WO2019113269A1
(fr)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|